NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 6 September 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Iftab Akram Present for all items
4. Dr Alex Cale Items 1 to 5.2.2
5. Michael Chambers Present for all items
6. Dr Prithwiraj Das Present for all items
7. Chamkhor Dhillon Present for all items
8. Dr David Foreman Present for all items
9. Dr Rob Forsyth Present for all items
10. Dr Natalie Hallas Present for all items
11. Dr Nigel Langford Present for all items
12. Dr Andrea Manca Present for all items
13. Iain McGowan Present for all items
14. Ugochi Nwulu Present for all items
15. Stella O’Brien Present for all items
16. Professor Subhash Pokhrel Present for all items
17. Professor Andrew Renehan Present for all items
18. Professor Matthew Stevenson Items 1 to 6.1.3
19. Professor Paul Tappenden Present for all items

NICE staff present

Linda Landells, Associate Director Items 1 to 4.2.2

Ross Dent, Associate Director Items 5 to 6.2.2

Jasdeep Hayre, Associate Director Items 5 to 6.2.2

Kate Moore, Project Manager Items 1 to 5.2.2

Louise Jafferally, Project Manager Present for all items

Celia Mayers, Project Manager Items 6 to 6.2.2

Fatima Chunara, Heath Technology Assessment Adviser Items 1 to 4.2.2

Vicky Kelly, Heath Technology Assessment Adviser Items 5 to 5.2.2

Louise Crathorne, Heath Technology Assessment Adviser Items 6 to 6.2.2

Sarah Wilkes, Heath Technology Assessment Analyst Items 1 to 4.2.2

Lewis Ralph, Heath Technology Assessment Analyst Items 5 to 5.2.2

Harsimran Sarpal, Heath Technology Assessment Analyst Items 6 to 6.2.2

Benjamin Gregory, Business Analyst, RIA Present for all items

Catrin Austin, Technical Analyst, Commercial Risk Assessment Items 6 to 6.2.2

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment, Present for all items

Neha Jiandani, Technical Analyst, Commercial Risk Assessment Items 1 to 4.2.2

Stephen Norton, Technical Analyst, Commercial Risk Assessment Items 1 to 4.2.2

Olivia Havercroft, Senior Medical Editor Items 1 to 4.2.2

Hayley Garnett, Senior Medical Editor Items 5 to 5.2.2

Anna Sparshatt, Senior Medical Editor Items 6 to 6.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 5 to 5.1.3

Lyn Davis, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Rosalee Mason, Coordinator, MIP Items 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Mohammed Towhasir, Administrator, TA Items 1 to 4.2.2

Iain Cannell, Administrator, TA Items 5 to 5.2.2

Leah Kelly, Administrator, TA Items 6 to 6.2.2

NICE staff observers present

Sally Doss, Heath Technology Assessment Adviser Items 5 to 6.2.2

Stephen Duffield, Senior Adviser in Data and Analytics Items 5 to 5.2.2

Seamus Kent, Senior Adviser in Data and Analytics Items 6 to 6.2.2

Anna Murray-Cota, Heath Technology Assessment Analyst Items 5 to 5.2.2

Catie Parker, Heath Technology Assessment Analyst Items 5 to 6.2.2

Ziqi Zhou, Heath Technology Assessment Analyst Items 6 to 6.2.2

External assessment group representatives present

Keith Cooper, Southampton Health Technology Assessment Centre (SHTAC), Items 1 to 4.1.3

Jonathan Shepherd, Southampton Health Technology Assessment Centre (SHTAC), Items 1 to 4.1.3

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Isaac Corro Ramos, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Graham Scotland, Aberdeen HTA Group Items 6 to 6.1.3

Lorna Aucott, Aberdeen HTA Group Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 4.2.2

Professor Christopher Fox, Clinical expert, nominated by RC Physicians, Items 1 to 4.1.3

Dr Wendy Osborne, Clinical expert, nominated by Roche, Items 1 to 4.1.3

Dr Graham Collins, Clinical expert nominated by Association of Cancer Physicians, Items 5 to 5.1.3

Dr Keith Wilson, Clinical expert nominated by Anthony Nolan , Items 5 to 5.1.3

Cerys Thompson, Patient expert nominated by Blood Cancer UK, Items 5 to 5.1.3

Dr Graham Collins, Consultant Haematologist and Lymphoma MDT lead, Clinical expert nominated by Kite, Items 6 to 6.1.3

Dr Tobias Menne, Consultant Haematologist, Clinical expert nominated by RC Physicians, Items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 2 August 2022.

### Appraisal of polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Roche.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has co-ordinated a training programme (with the University of Utrecht) for Roche (submitting company) on Real World Evidence, which did not involve specific consideration of Roche's products and he has participated in an advisory panel for Pfizer (possible comparator) in an unrelated disease area (prostate cancer). It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared financial interests as he has carried out paid advisory boards with Roche in an unrelated area - multiple sclerosis. It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
* Nominated clinical expert Professor Christopher Fox declared the following interests:
* He has received honoraria and consultancy fees from Roche (company) for advisory boards and educational activities, some of which relate directly to the technology being appraised.
* He has also received honoraria and consultancy fees from other companies (not comparators in this appraisal) relating to the same disease area.
* He also declared that in his role as NCRI high-grade lymphoma study group Chair, he is involved in ongoing clinical trials that involve the technology in question. These are academic-led studies with funding support and drug provision from Roche (company).

It was agreed his declarations would not prevent Professor Fox from providing expert advice to the committee.

* Nominated clinical expert Dr Wendy Osborne declared financial interests as she has received conference fees, advisory board, and speaker fees from Roche (company). She also declared indirect interests with other companies including Pfizer (comparator). It was agreed her declarations would not prevent Dr Osborne from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Paul Tappenden, Dr David Foreman, and Stella O’Brien
  1. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10785>

### Appraisal of axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies (CDF Review of TA559) [ID3980]

* 1. Part 1 – Open session
     1. The chair Dr Richard Nicholas welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Kite, a Gilead company.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has co-ordinated a training programme (with the University of Utrecht) for Roche (possible comparator) on Real World Evidence, which did not involve specific consideration of Roche's products and he has participated in an advisory panel for Pfizer (possible comparator) in an unrelated disease area (prostate cancer). It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared financial interests as he has carried out paid advisory boards with Roche in an unrelated area - multiple sclerosis. It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal
* Committee member Stella O’Brien declared personal interests as she has joined the Genetic Alliance UK Working Group for Patient and Public Involvement and Engagement for Advanced therapy medicinal products (ATMPs). It is the largest alliance of organisations supporting people with genetic, rare, and undiagnosed conditions in the UK. It was agreed her declaration would not prevent Stella from participating in discussions on this appraisal.
* Nominated clinical expert Dr Graham Collins declared financial interests as he has received honoraria for speaker and consultancy work from Kite / Gilead and Novartis. It was agreed his declarations would not prevent Dr Collins from providing expert advice to the committee.
* Nominated clinical expert Dr Keith Wilson has declared the following interests:
* He has received travel grants from Kite/Gilead
* He has attended Advisory Boards and Speakers’ Bureau and received honoraria from Kite/Gilead, Novartis, and Celgene.
* He has received Institutional Research Grants – The SWBMT Programme is currently in receipt of funding from Kite/Gilead under its Fellowship Scheme and has a Kite Fellow who oversees the rehabilitation programme.
* He is currently in discussions with Kite/Gilead regarding a possible research collaboration.
* He is a member of the Industry Advisory Group of Cell and Gene Therapy Catapult which advises the UK Government on issues pertinent to adoption of ATMPs.

It was agreed his declarations would not prevent Dr Wilson from providing expert advice to the committee.

* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Natalie Hallas, Dr Alex Cale, and Ugochi Nwulu.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10951>

### Appraisal of axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Kite, a Gilead company.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has helped co-ordinate a (University of Utrecht) training programme in Real World Evidence for Roche, which did not involve consideration of any Roche products. Both Pfizer and Roche are manufacturers of possible comparator therapies. It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared financial interests as he has carried out paid advisory boards with Roche in an unrelated area - multiple sclerosis. It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal
* Committee member Stella O’Brien declared personal interests as she is a member of the Genetic Alliance UK Working Group for Patient and Public Involvement and Engagement for Advanced therapy medicinal products (ATMPs). It is the largest alliance of organisations supporting people with genetic, rare, and undiagnosed conditions in the UK. It was agreed her declaration would not prevent Stella from participating in discussions on this appraisal.
* Nominated clinical expert Dr Graham Collins declared financial interests as he has received honoraria for speaker and consultancy work from Kite / Gilead and Novartis. It was agreed his declarations would not prevent Dr Collins from providing expert advice to the committee.
* Nominated clinical expert Dr Tobias Menne declared direct financial interests as he has received:
* travel grants from Amgen, Jazz, Pfizer, Bayer, Kyowa Kirin, Celgene, Kite/Gilead, Janssen, and Takeda,
* honoraria for advisory board meetings from Kite/Gilead, Amgen, Novartis, Pfizer, Celgene/BMS, Daiichi Sankyo, Atara, Roche, Janssen
* honoraria for lectures from Kite/Gilead, Takeda, Janssen, Roche, Servier, Novartis, Celgene, and Research funding from Janssen, Astra Zeneca, Novartis.

It was agreed his declarations would not prevent Dr Menne from providing expert advice to the committee.

* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10578>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 4 October 2022 and will start promptly at 09.30.